Evotec AG implements ConturELN Contur Software’s Enterprise ELN system
STOCKHOLM, Sweden, May 18, 2010. – Contur Software is pleased to announce that Evotec AG (Frankfurt Stock Exchange: EVT; TecDAX), a leading provider in the discovery and development of novel small molecule drugs, has selected ConturELN as their Enterprise ELN. The electronic lab notebook system from Contur was chosen after a thorough selection process.
ConturELN covers Evotec’s global research activities across all drug discovery disciplines and has been integrated with Evotec’s existing cheminformatics platform.
“The ability of ConturELN to satisfy the detailed demands of our global Chemistry, Biology, Pharmacology, Structural Biology and Analysis teams provides us with a significant advantage in helping us achieve effective and integrated data management, delivering benefits to our drug discovery partners”, says Dr. Steve Courtney, Senior Vice President Drug Discovery at Evotec AG.
“We are pleased that Evotec has chosen ConturELN as its ELN provider. Implementing an Enterprise ELN and satisfying the needs of all disciplines is a challenge which requires the right combination of software, methodology and people”, says Mr. Thomas Rozlucki, Director Marketing at Contur Software.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. www.evotec.com.
